Contact a Rep at EISAI ENGAGE

This site is intended for U.S. health
care professionals only.

LENVIMA® (lenvatinib) capsules 10 mg and 4 mg logo
Select an Indication
1st-Line treatment of uHCC RAI-refractory DTC 1st-Line treatment of aRCC 2nd-Line treatment of aRCC Advanced EC
LENVIMA® for first-line unresectable hepatocellular carcinoma

LENVIMA uHCC Video Library

REFLECT: A phase 3 clinical trial in patients with uHCC1,2

Dr Kim reviews the safety and efficacy data from REFLECT, a head-to-head clinical trial comparing OS, PFS, and ORR of first-line LENVIMA vs sorafenib.

Managing adverse reactions that may occur with LENVIMA

Dr Edward Kim and Alana Rothman, FNP-BC, discuss how they recognize, monitor, and manage adverse reactions when treating their patients with LENVIMA.

An exploratory post hoc analysis of patients who progressed from CP-A to CP-B in REFLECT trial

Dr Edward Kim discusses efficacy and safety in patients who progressed from Child-Pugh class A to Child-Pugh class B within 8 weeks of randomization in the REFLECT trial.3

HCP=health care provider; uHCC=unresectable hepatocellular carcinoma; REFLECT=A Multicenter Randomized, Open-Label, Phase 3 Trial to Compare the EFficacy and Safety of LEnvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With UnreseCtable HepaTocellular Carcinoma; OS=overall survival; PFS=progression-free survival; ORR=overall response rate; CP-A=Child-Pugh A; CP-B=Child-Pugh B.

Featured HCPs

Edward J Kim, MD, PhD

Associate Professor of Medicine

Division of Hematology and Oncology

UC Davis Medical Center

Sacramento, California

Sponsored by Eisai, Dr Edward J Kim was paid for his participation in this video.

Dr Kim is an adult medical oncologist specializing in treating gastrointestinal malignancies including pancreatic, nepatocellular, biliary, esophageal, gastric, and colorectal cancers. Dr Kim received his doctorate and medical degree from Stony Brook University in New York. He then went on to complete his residency in internal medicine, as well as his fellowship, through the University of Michigan in Ann Arbor.

Dr Kim's research includes developing and conducting clinical trials for gastrointestinal malignancies, as well as novel pancreatic cancer treatments. Dr Kim is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. He has also served on committees for a variety of organizations and has contributed to numerous studies, reviews, and articles.

Alana L Rothman, FNP-BC

Advanced Oncology Certified Nurse Practitioner (AOCNP)

Division of Hematology and Oncology

UC Davis Comprehensive Cancer Center

Sacramento, California

Sponsored by Eisai, Alana L Rothman was paid for her participation in this video.

Alana L Rothman, FNP-BC, is a licensed nurse practitioner with a Master of Science in nursing from the University of California, San Francisco, where she also received a Master of Arts in endocrinology. She serves as a nurse practitioner supervisor under the Division of Hematology and Oncology at the UC Davis Comprehensive Cancer Center in Sacramento, California. Ms. Rothman is currently an Advanced Practice Provider (APP) Fellowship Advisory Board member and was instrumental in developing UC Davis's first APP fellowship in oncology.

Ms. Rothman also spent time as a managing editor for the scientific content department of Biocompare. She has been a recipient of the Daisy Award and has written for numerous publications including The Oncology Connection.

Resources uHCC Home